The history of biofeedback therapy in neuromuscular rehabilitation began with the discovery in 1830 that electrical events emanated from the surface of a muscle during its contraction1. The prototype forerunner of the current electromyogram (EMG) appeared in 19282. Reports of the application of biofeedback (BFB) techniques for the treatment of various neuromuscular disorders began to appear in the late 1950s and early 1960s3-5. In the next three decades, enthusiastic case series, and later randomized controlled trials, were published. The results of the latter more rigorous trials were mixed in their appraisal of its efficacy68. Finally over the last three years, quantitative literature overviews, or meta-analyses, have been published in an attempt to elucidate the potential role of this modality more adequately9-11. Although the various reports have described its use in a wide variety of neuromuscular disorders including spinal cord injury12, spastic torticollis and other dystonias13, cerebral palsy and peripheral nerve damage14, by far the greatest area of investigation and concomitant utilization has been post-stroke rehabilitation. This paper will describe some of the basic physiological constructs of BFB, and the functional aspects of applying it in the clinical setting. The special problems related to research in stroke rehabilitation will be reviewed with special reference to BFB. However, the main focus and purpose of this work will be to provide the reader with an assessment of the overall efficacy of this modality in stroke rehabilitation.
INTRODUCTION
The history of biofeedback therapy in neuromuscular rehabilitation began with the discovery in 1830 that electrical events emanated from the surface of a muscle during its contraction1. The prototype forerunner of the current electromyogram (EMG) appeared in 19282. Reports of the application of biofeedback (BFB) techniques for the treatment of various neuromuscular disorders began to appear in the late 1950s and early 1960s3-5. In the next three decades, enthusiastic case series, and later randomized controlled trials, were published. The results of the latter more rigorous trials were mixed in their appraisal of its efficacy68. Finally over the last three years, quantitative literature overviews, or meta-analyses, have been published in an attempt to elucidate the potential role of this modality more adequately9-11. Although the various reports have described its use in a wide variety of neuromuscular disorders including spinal cord injury12, spastic torticollis and other dystonias13, cerebral palsy and peripheral nerve damage14, by far the greatest area of investigation and concomitant utilization has been post-stroke rehabilitation. This paper will describe some of the basic physiological constructs of BFB, and the functional aspects of applying it in the clinical setting. The special problems related to research in stroke rehabilitation will be reviewed with special reference to BFB. However, the main focus and purpose of this work will be to provide the reader with an assessment of the overall efficacy of this modality in stroke rehabilitation. METHODS A MEDLINE search was conducted by use of the keyword 'Biofeedback'. This indexes articles dating back to 1966, well before the first clinical trials on BFB began to appear. One thousand four hundred and nineteen items were cited. Abstracts of all articles relevant to the use of biofeedback in stroke rehabilitation were reviewed. Particular attention was paid to randomized controlled trials, meta-analyses, critiques of research or applications of BFB, and recent reports on technological advances in the field. The tables of contents of retrieved articles were reviewed for other relevant articles. BACKGROUND Cerebrovascular disease remains an extremely important health problem. In the United Kingdom alone, each year 130000 new strokes occur, and 64000 individuals die as a result of this ailment15. The actual incidence of stroke is 2.2 per 100016. Despite advances in the treatment of important risk factors such as hypertension, the incidence of stroke has not been declining of late, perhaps due to the aging of the population in general, a problem which is expected to progress'7. Each health district can expect to care for 1500 episodes annually at a cost of £3 million18. In 1988 the King's Fund Consensus Statement was published. This document recognized at once the importance of stroke in the United Kingdom and the lack of organization and standardization of the delivery of services for this disorder18. As a result stroke rehabilitation in particular began to be widely discussed in the health districts, and it received a significant boost. Subsequent papers have delineated the lack of objective evidence for the efficacy of various neuromuscular rehabilitative techniques in stroke and the need for further research in the area'9.
Normal physiology
The EMG enabled researchers to monitor the fundamental functional substrate of neuromuscular function, the motor unit. This represents all of the muscle fibres which are innervated by the branches of a single axon. It was subsequently discovered that subjects could learn specifically to gain control over the selective activation of a single such motor unit, an ability that is the basis for all motor training, which involves the progressive activation and inhibition of larger groups of motor units. Selective alteration in the rate of firing of individual units is another important aspect of normal physiology, leading to increased strength of contraction, and this too is amenable to BFB modulation20.
Altered physiology in stroke
The physiological impairment and consequent functional limitation in stroke involves both decreased force of muscle contraction and overactive but dysfunctional contractions known as spasticity. These exist in opposing groups of Technology Assessment Group, Department of Healfth Policy and Management, Harvard School of Public Health, Room LL-A7, 677 Huntington Ave, Boston, MA 02115, USA Correspondence to: Morton Glanz muscles, resulting in impaired volitional movement. An important additional phenomenon is that of muscle synergies or the stereotypical synchronous contraction of several closely grouped muscles, instead of the finely controlled selective contraction and relaxation of individual muscles which is important for normal mature motor function.
Analysis of the stroke rehabilitation literature is rendered difficult by the interchangeable use of imprecise terms such as function, limitation, impairment, and disability. Similarly, the lack of standard staging taxonomy has hindered the critical evaluation of rehabilitation modalities in stroke, and certainly may explain a lot of the disparity of results in the BFB trials. In a recent review, Duncan has proposed looking at stroke disability at three levels: physiological impairment (e.g. loss of range of motion), functional limitation (e.g. inability to walk) and actual disability, such as the inability to dress oneself. She has proposed a staging system based upon these descriptive elements which is currently being validated21.
Three basic physiological constructs have been the target of BFB treatment in stroke. These are the functions of the shoulder, wrist-hand, and ankle joints, as detailed by Basmajian20. As a result of weakness of the rotator cuff, levator scapulae, and teres minor muscles, the shoulder joint, which is dependent on these muscles for anatomic integrity during normal movement, becomes lax with eventual downward subluxation of the humeral head. This in turn renders the joint functionally useless. Weakness of extensors, but more importantly spasticity of flexor musculature, is of major significance in hand and wrist function. Loss of ankle range of motion is the key factor in analysing gait disability in stroke. In the swing phase of gait, during which the foot must dorsiflex, the combination of weakness of the anterior tibial musculature and spasticity of the gastrocnemius and soleus muscles impairs this process.
PRINCIPLES OF BIOFEEDBACK THERAPY
The mechanism by which BFB may help in the rehabilitation of the stroke patient is not clear. Wolfe has noted the various possibilities, concluding that all represent con-jecture6. No definitive studies since the time of his observation were uncovered in the process of this review. A favoured explanation is that the patient, through the artificial proprioception provided by the BFB apparatus, is able to gain conscious control over subliminal yet undamaged upper neuron pathways which are in turn able to subserve the missing functions responsible for the altered physiology.
Biofeedback units range in size and complexity from small individual portable units, suitable for home use, to complex models with more advanced capabilities. All share certain basic elements. These include one or more channels from which emanate bipolar electrodes capable of recording activity in individual muscles, mechanisms for amplifying and integrating the recorded EMG signal, and a scheme to display the output, which can be of an auditory or visual nature. Newer more complex models contain advanced integrative and memory capabilities22.
In practice BFB is combined with traditional physiotherapy, with the two modalities being integrated by the therapist in complementary fashion. Many studies evaluating the efficacy of BFB have focused the research question in terms of BFB versus traditional physiotherapy. Wolfe has argued against this artificial dichotomy, citing the co-dependence of the modalities23. In an actual session the therapist will apply the recording electrodes to one or more muscles, asking the patient to try to activate (in the case of paresis) or relax (in the case of spasticity or undesirable synergy) the respective muscle. Judgement is therefore required regarding such factors as the location and spacing of electrodes, reflecting the therapist's assessment of the altered physiology. The artificial proprioceptive feedback provided by the auditory or visual output of the unit enables the patient to become 'aware' of volitional changes in motor unit activity and thus restore functional patterns of movement. How various parameters of BFB can affect the outcome of treatment with special reference to the reported clinical trials will be discussed below. Additional parameters include the frequency and duration of individual sessions, the type of feedback rendered (continuous versus bandwidth)24, and whether simple or more complex, purposeful movement patterns are utilized25. These factors amongst others are important in considering the heterogeneity of treatment effects reported in the various trials of BFB efficacy.
In a representative Boston rehabilitation hospital BFBassisted physiotherapy is billed at $160 per hour, while routine physiotherapy is billed at $148 per hour. As is often the case with charges they may not reflect the true resource cost26. Nevertheless the similarity of the charge regardless of whether BFB is utilized in the treatment session suggests that BFB is not labour or resource intensive. The basic BFB unit is cheap ($2000) and durable. Finally the fact that therapy can be applied at home, by patient or family, lessens the drain on a national health budget.
THE EFFICACY OF BIOFEEDBACK IN STROKE
The initial case reports and small uncontrolled series on BFB therapy in stroke were quite enthusiastic, often citing rather dramatic and remarkable recoveries from what were thought to be permanent disabilities. Case series described instances where patients, thought to have long since plateaued in their rehabilitation course, discarded their cumbersome foot braces and walked away free14. However, as noted previously, subsequent controlled series were more mixed in their conclusions. There are five potential sources to explain disparate conclusions in clinical trials. These include differences in the treatment, populations exposed, outcome measures, random variation, and systematic variation also known as bias. It is instructive to examine how these facets might relate to the BFB studies.
Treatment
There is no standard way to admninister BFB in the treatment of the paresis and spasticity of stroke patients22. By nature the treatment requires ad hoc decisions by the therapist regarding electrode placement and joint positioning, based on the perceived status of the abnormal physiology. The way traditional physiotherapy is integrated into the BFB training depends upon the attitude and skill of the therapist regarding both modalities. The individual trial can specify the frequency, duration, and total number of training sessions, though these parameters will obviously vary between trials. Additionally the way the feedback is provided to the patient (continuous versus bandwidth) can also affect the success of motor learning24.
Finally the use of purposeful activity (walking) versus undifferentiated activity (range of motion of the ankle joint at rest) has been shown to influence motor training25. This situation is in stark contrast to a chemotherapy trial where a standard dosage schedule of a specific drug can be uniformly applied, and differences across trials can be more easily scrutinized28.
Patient population This is perhaps the greatest potential source of heterogeneity among trials. Wolfe has enumerated the critical aspects of stroke patients which are of concern in this regard6. These include the time post-stroke of treatment application, since less and less spontaneous recovery can be expected after 3 months29. If treatment and control groups are not evenly matched for this parameter, an obvious bias can therefore be introduced. The actual territory and extent of the stroke needs to be considered. For example there is some evidence that patients with middle cerebral artery occlusion fare less well in rehabilitation. Only one study has attempted to account for this variable in its planning30. Associated neurological features such as density of paresis, dominant versus non-dominant side involvement, proprioceptive loss, aphasia and cognitive deficits can impact on the success of any rehabilitation programme. Age, associated affective disorder, and motivational factors are additional features to consider in this regard. Exactly how these factors relate to success in BFB for stroke is unclear and controversial31'32. In these cited studies Wolfe has presented some evidence that time post-stroke did not influence the likelihood of success with BFB, at least for the lower extremity. As noted above, the development of a proper staging modality could greatly facilitate research in this area.
Outcome measures
The endpoints utilized in the various clinical trials on BFB therapy in stroke have ranged from the simple quantification of the integrated EMG signal33 to the performance of complex tasks such as drinking from a glass25. The arguments regarding what constitutes an appropriate endpoint in stroke rehabilitation are complex and have been reviewed by Ernst34. While it seems obvious that a decrease in the level of disability (as per Duncan's scheme) would be the ultimate goal of any therapy, such measurements are not easy to obtain in a valid and reliable manner35'36.
Additionally, they are reported in an ordinal or discontinuous integral fashion and thus do not lend themselves to parametric statistical analysis. A frequently utilized endpoint, range of motion, is considered critical to the recovery of joint usage37, though not representing, of itself, a 'function'. It has the statistical advantage of measurement on a continuous numerical scale, but has been criticized as lacking in reproducibility35'36. Wolfe has suggested the use of speed, distance and force as endpoints that circumvent such concerns6. When assessing the overall efficacy of BFB in stroke rehabilitation, the observer must be aware of these considerations.
Random variability
All of the stroke-related BFB trials have been small. Even if BFB had a specific positive treatment effect, the results of individual small trials might point in different directions. Such differences are accountable by measurement error or day-to-day biological variability in the subjects. Stroke patients are noted to display such random variability in the degree of functional impairment exhibited6. In general the small size of individual trials in the face of such variability would tend to widen the confidence intervals around a calculated positive treatment effect, and hence reduce the level of statistical significance. This phenomenon, frequently designated as type 2 error, is explored in the quantitative overview or meta-analytic technique discussed later in this paper.
Systematic error
Multiple forms ofbias which can affect the validity of a clinical trial have been well described38. Most ofthese relate to the fact that patients, planners and observers may have a vested interest in a particular outcome. The double-blind randomized controlled clinical trial is the study structure of choice to minimize such bias. No trials are of this arcadian design, however, on BFB therapy of stroke. In fact of the trials completed from 1960-1982 and critiqued by Wolfe, only 42% contained a control group at all6. He does acknowledge the tremendous operational difficulties of carrying out a double-blind study on this subject in the rehabilitation setting. Furthermore, most of the controlled trials do not even utilize sham treatment for the control group, decreasing the strength of design and clouding the issue of whether BFB, even if it is 'effective', works through a specific neurophysiological mechanism or merely provides a nonspecific motivating influence, engendered in part by the seductive influence of 'high tech' factors22. As might be expected, the randomized controlled trials in general have been less enthusiastic in their reporting of the efficacy of BFB.
Meta-analyses of BFB therapy for stroke
Just as the double-blind randomized controlled trial is the paradigm for the ideal study, a well conducted meta-analysis embodies the essential elements of the 'stateof the art' review article3940. This discipline, developed initially for application in the social sciences, was first applied in the medical sciences by Chalmers to address the avalanche of (often conflicting) clinical trial data. Its strength lies in the ability to assess the significance of ostensibly small but potentially important clinical results demonstrated in the individual trials, by the pooling of outcomes. The fact that randomized trials in general are too small to demonstrate conclusively such benefits has been the impetus behind the formation of the Cochrane Collaboration41. The question of validity is approached by systematically including only high quality studies, or at least considering the effect on the analysis of including trials of lesser merit. Quality in this sense generally refers to the extent of proper randomization and blinding.
In the last 2 years, three meta-analyses on the efficacy of BFB therapy in stroke rehabilitation have been published. By critically examining the methodology and conclusions of these papers, one can hope better to assess the efficacy question as well as generate hypotheses regarding modulating factors. Table 1 summarizes some salient features of these three analyses.
It is notable that, even though all three studies set out to ask the same research question, there was little overlap in the included trials. Only one study was used in all three analyses. The greatest number of trials common to any two analyses was three. This lack of congruence was related to: (1) endpoint(s) chosen; (2) stringency of validity criteria for a study to be included; (3) comprehensiveness of the search The Schleenbaker analysis looked at functional outcomes rather than more basic physiological measures, with the rationale that only such endpoints are of ultimate significance in the natural history of stroke recovery. In doing so they combined different endpoints all representative of 'function' using the effect size method. The study by Glanz et al. utilized the most consistent endpoint, i.e. change in range of motion. The rationale is that a meta-analysis is on strongest grounds when the critical elements of the included studies (patients, exposures, outcome variables) are as similar as possible39. The Moreland analysis dichotomized its selected studies into groups representative of functional and more basic physiological constructs (termed 'impairment'). The analysis was limited to outcomes expressed for upper extremity alone, while the former two looked at both upper and lower extremity endpoints. As noted, the upper extremity is more recalcitrant to rehabilitation efforts in stroke.
The concept of validity in a clinical trial relates to how well the design translates into an objective study of the research question. This signifies the avoidance of systematic error or bias. The methods of Oxman42 or Chalmers43 can be used to assess the individual validity of studies to be included in a meta-analysis. In this regard the Moreland study is the most rigorous of the three, selectively excluding studies which did not measure up to a predetermined matrix of criteria, and also measuring the agreement amongst the authors of their study regarding the parameters of merit. The Glanz study measured quality according to the method of Chalmers. The scores were all within a low range and studies were not excluded or otherwise weighted on this basis. (A previous paper which looked at this system found no correlation between outcomes of randomized controlled trials and the quality score. A possible reason proffered was that the strength of the randomized controlled design supersedes the importance of the detailed quality scoring system44.) The Schleenbaker analysis was least rigorous in this regard, in that non-randomized trials were included45'6. Chalmers had previously shown that non-randomization tends to bias results toward the treatment group47. It is notable that the studies with the largest effect sizes in the Schleenbaker analysis were non-randomized.
The difficulty in retrieving all relevant trials for a metaanalysis has been well documented. In one study only 29% of the trials were elicited by use of a standard computerized data base48. The Moreland search protocol seems the most exhaustive in this regard, even including a search for unpublished studies.
The validity of a meta-analysis, as with an individual trial, relates to the adherence to a predetermined protocol which is designed to minimize bias. Again the Moreland study, as far as can be discerned from the individual papers, process.
Volume 90 Jan uary 1 997 seems mos ngorous. Regarding data analysis the Schleenbaker and Glanz papers used the effect size method of Glass49. This is a parametric technique, thus presupposing that the data are in the form of continuous variables in a roughly normal distribution. (Parametric analysis of discontinuous variables may be acceptable only with very large sample sizes.) The former analysis does incorporate some results with discontinuous scales. Additionally, when more than one outcome was available in a study for inclusion in the analysis, it is not clear how the selection was made. Neither study justified the assumption of normality in individual study data, for example by commenting on the rough appearance of the distributions. The Moreland study acknowledged the difficulty of using a parametric technique given the above concerns and therefore organized the data into a dichotomous format based upon the presence of improvement in the designated endpoint. This approach led to the loss of some quantitative information, but subverted the stated problem of combining discontinuous and somewhat dissimilar variables, as well as concerns over the nature of the distribution of the data set. All three studies reported a pooled mean outcome in favour of BFB therapy for stroke although only in the Schleenbaker study was the result statistically significant at the P <0.05 level, one-tailed. The mean effect sizes noted (0.81 for Schleenbaker and 1.50 for Glanz) would be considered 'large' by convention50. In fairness it should be noted, however, that such qualitative statements about effect size magnitudes and their resultant clinical significance are controversial51. The pooled odds ratio for the Moreland study (2 .2) was interpreted by the author, using the 'number needed to treat' format of Sackett38, as being small: seven need to be treated to help one patient. It is not clear, in view of the potential impact of stroke disability on quality of life, that this represents an unacceptable level of efficacy. To claim such would probably require a degree of analysis beyond the scope of this paper. The Glanz study did calculate the magnitude of type 2 error, which quantifies the probability that a true treatment effect was present but the sample size was too small to demonstrate it. This was equal to 0.73 for the upper extremity and 0.71 for the lower, which are in fact quite large. In planning a clinical trial an investigator generally aims for a type 2 error of0.10 or less. Moreland was unable to calculate a type 2 error for technical reasons. One randomized controlled trial has been reported since the publication of these meta-analyses52. This was a positive study in favour of BFB, but as it contained only 16 patients, we doubt if it would have materially reduced the type 2 error ofthe Moreland and Glanz studies. CONCLUSION Research efforts into limiting neuronal damage in the acute phase of stroke are still at an embryonic stage, so the major focus remains on rehabilitative efforts. Research and organization of rehabilitation services including BFB have been desultory, and these have been earmarked for upgrading18. This is an area where small improvements, such as a few extra degrees of range of motion in a paretic ankle joint, can make a big difference in level of disability, perhaps the difference between independence and institutionalization. Although a broad-brush statement for the efficacy of BFB therapy for stroke cannot be made at this time, certain considerations merit emphasis.
There is a rich tradition of basic neuroscience research behind BFB therapy. This is complemented by applied research, especially the efforts of Basmajian and Wolfe. That randomized controlled trials were not as enthusiastically supportive of efficacy as earlier case series or historically controlled studies could be said of almost any treatment47. The multiple layers of difficulty involved in stroke rehabilitation research in general, and biofeedback in particular, would make this a 'Gordian knot' for even the most resolute of clinical trialists. Three quantitative overviews recently published in an attempt to summarize the scientific clinical experience of BFB in stroke have arrived at different yet potentially consistent conclusions: one with a statistically significant positive result; another with a large mean effect size not statistically significant but with a very large type 2 error; and a third, concentrating on the more problematic upper extremity, with a positive pooled result but not significant at the P<0.05 level. It is certainly plausible that inadequate sample size and a failure properly to stratify trial enrollees with reference to the potential for neurorecovery can explain the lack of statistical significance of the latter two meta-analyses. Furthermore, most of the trials are old and their results alone do not reflect subsequent technological advances and the learning curve which accompanies them. The least that can be said for BFB therapy in stroke rehabilitation is that it offers hope for a proportion of those with this affliction, and that controlled research in this area should be strongly encouraged.
In summary, despite the burgeoning of clinical trials and other scientific evidence there is paradoxically insufficient evidence to guide the majority of clinical decisions. Even the best planned studies rarely give enough information to apply the overall conclusions to individual subsets of patients. Given cost and resource considerations, it is unlikely that such information will be forthcoming.53 As a recent publication noted, clinicians will often have to make decisions based upon '. . a considered review of the totality of evidence'54.
